Irbesartan + Hidroclorotiazida Aurovitas (Hydrochlorothiazide, Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone secretion. This results in relaxation of vascular smooth muscle and reduced sodium and water retention, contributing to a decrease in systemic blood pressure.

Hydrochlorothiazide inhibits the Na⁺/Cl⁻ cotransporter in the distal convoluted tubule of the kidney, reducing reabsorption of sodium and chloride. The resulting diuresis lowers plasma volume, which helps to decrease peripheral resistance and lower blood pressure.

The prescribed dose of Irbesartan + Hidroclorotiazida Aurovitas is determined by the treating physician based on the patient’s blood pressure, renal function, and concomitant medications. Dosage adjustments are individualized; patients should follow the prescriber’s instructions and not change the regimen without medical advice.

The safety of Irbesartan + Hidroclorotiazida Aurovitas during pregnancy has not been established, and the combination is generally contraindicated because of potential fetal toxicity. Use during lactation is also not recommended unless a healthcare professional determines that the benefits outweigh the risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy agents, the irbesartan/hydrochlorothiazide combination offers dual mechanisms—RAAS blockade and diuresis—in a single tablet, which can improve adherence and provide greater blood‑pressure reduction. It is often chosen when a single agent does not achieve target levels, whereas alternatives may require separate prescriptions.

Irbesartan + Hidroclorotiazida Aurovitas tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Do not store in areas of high humidity or extreme heat, and keep out of reach of children.

The product is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed. Consistent timing each day helps maintain stable blood‑pressure control.

Patients should be alert for signs of severe hypotension, electrolyte disturbances such as low potassium or sodium, acute kidney injury, and angioedema. If symptoms like dizziness, fainting, swelling of the face or throat, or sudden changes in urine output occur, medical attention should be sought promptly.